Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer
Karinna Saxby, Carolyn Nickson, G Bruce Mann, Allan Park, Hannah Bromley, Louiza Velentzis, Pietro Procopio, Karen Canfell, Dennis Petrie
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | TAYLOR & FRANCIS LTD | Published : 2021
Background:Although evaluations of breast cancer screening programs frequently estimate quality-adjusted life-year (QALY) losses by stage, other breast cancer characteristics influence treatment and vary by mode of detection - i.e. whether the cancer is detected through screening (screen-detected), between screening rounds (interval-detected) or outside screening (community-detected). Here, we estimate the association between early-stage invasive breast cancer (ESIBC) characteristics and treatment-related QALY losses.Methods:Using clinicopathological and treatment information from 675 women managed for ESIBC, we estimated the average five-year treatment-related QALY loss by detection group. ..View full abstract
Awarded by Cancer Australia Priority-driven Collaborative Cancer Research Scheme
This work was funded by the Cancer Australia Priority-driven Collaborative Cancer Research Scheme (project grant 1066771).